Summit Therapeutics Net Worth
Summit Therapeutics Net Worth Breakdown | SMMT |
Summit Therapeutics Net Worth Analysis
Summit Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Summit Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Summit Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Summit Therapeutics' net worth analysis. One common approach is to calculate Summit Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Summit Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Summit Therapeutics' net worth. This approach calculates the present value of Summit Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Summit Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Summit Therapeutics' net worth. This involves comparing Summit Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Summit Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Summit Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Summit Therapeutics' net worth research are outlined below:
| Summit Therapeutics is way too risky over 90 days horizon | |
| Summit Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (614.93 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (76.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Summit Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 84.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Alarm bells ringing as EV transition hits UK auto industry |
Summit Therapeutics Quarterly Good Will |
|
Summit Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Summit Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Summit Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Summit Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Summit Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Summit Therapeutics PLC backward and forwards among themselves. Summit Therapeutics' institutional investor refers to the entity that pools money to purchase Summit Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Trust Advisors L.p. | 2024-06-30 | 788.1 K | Pictet Asset Manangement Sa | 2024-06-30 | 708.6 K | Td Asset Management Inc | 2024-09-30 | 694.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 674.2 K | Citadel Advisors Llc | 2024-09-30 | 650.8 K | Goldman Sachs Group Inc | 2024-06-30 | 453.9 K | Balyasny Asset Management Llc | 2024-09-30 | 431.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 402.2 K | Barclays Plc | 2024-06-30 | 387.3 K | Baker Bros Advisors Lp | 2024-09-30 | 24.4 M | Vanguard Group Inc | 2024-09-30 | 10.9 M |
Follow Summit Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.97 B.Market Cap |
|
Project Summit Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.06) | (2.91) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (3.03) | (2.88) | |
| Return On Equity | (7.91) | (7.52) |
When accessing Summit Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Summit Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Summit Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Summit Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Summit Therapeutics PLC. Check Summit Therapeutics' Beneish M Score to see the likelihood of Summit Therapeutics' management manipulating its earnings.
Evaluate Summit Therapeutics' management efficiency
Summit Therapeutics PLC has return on total asset (ROA) of (0.3147) % which means that it has lost $0.3147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7321) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.91 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Summit Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 110.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 11 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.13 | 0.12 | |
| Net Current Asset Value | 128.1 K | 113.8 K | |
| Tangible Asset Value | 128.1 K | 113.8 K | |
| Tangible Book Value Per Share | 0.12 | 0.12 | |
| Enterprise Value Over EBITDA | 1.7 K | 1.7 K | |
| Price Book Value Ratio | 20.82 | 19.78 | |
| Enterprise Value Multiple | 1.7 K | 1.7 K | |
| Price Fair Value | 20.82 | 19.78 | |
| Enterprise Value | 1.7 B | 1.7 B |
Summit Therapeutics PLC has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 6.4 K | Quarterly Revenue Growth (1.00) | Return On Equity (0.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Summit Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Summit Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Summit Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Summit Therapeutics Corporate Filings
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 26th of September 2024 Other Reports | ViewVerify | |
ASR | 19th of September 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Summit Therapeutics Earnings per Share Projection vs Actual
Summit Therapeutics Corporate Management
| Elaine JD | Head Counsel | Profile | |
| Fong Clow | Chief Officer | Profile | |
| Betty Chang | Oncology Research | Profile | |
| Bhaskar Anand | Chief Finance | Profile | |
| Will Black | Head Technology | Profile |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.